Avances enartritis reumatoide
149
82. Ma, M.H.; Scott, I.C.; Kingsley, G.H.; Scott, D.L. Remission in early rheumatoid arthritis. J
Rheumatol 37, 1444-‐1453(2010).
83. Jayakumar, K.;Norton, S.; Dixey, J.; James, D.; Gough, A.;Williams, P.; et al. Sustainedclinical
remission in rheumatoid arthritis: prevalence and prognostic factors in an inception
cohort of patients treated with conventional DMARDS. Rheumatology (Oxford) 51, 169-‐
175(2012).
84.Shammas, R.M.; Ranganath, V. K.; Paulus, H.E. Remission in rheumatoid arthritis.
CurrRheumatol Rep12, 355-‐362(2010).
85. Brown, A.K.; Conaghan, P.G.; Karim, Z.; Quinn, M.A.; Ikeda, K.; Peterfy, C.G.; et al. An
explanation for the apparent dissociation between clinical remission and continued
structural deterioration inrheumatoidarthritis.ArthritisRheum58, 2958-‐2967(2008).
86.Maesea, J.; GarcíaDeYébenes,M. J.; Carmona, L.; Hernández-‐García, C.; el GrupodeEstudio
emAR II. Estudio sobre el manejo de la artritis reumatoide en España (emAR II).
Características clínicasde lospacientes. Reumatol Clin8, 236-‐242(2012).
87. Niedermann, K.; de Bie, R. A.; Kubli, R.; Ciurea, A.; Steurer-‐Stey, C.; Villiger, P. M.; et al.
Effectiveness of individual resource-‐oriented joint protection education in people with
rheumatoidarthritis: a randomizedcontrolled trial. Patient EducCouns82, 42-‐48(2011).
88. Steultjens, E. M.; Dekker, J.;
an den
Ende, C. H. Occupational
e Syst
Rev1,(2004). Disponibleen:
89. Hewlett, S.; Ambler, N.; A
l. Self-‐
management of fatigue in
group
cognitive-‐behavioural therapy. AnnRheumDis70, 1060-‐1067(2011).
90. Hagen, K. B.; Dagfinru
t al. Exercise
therapy for bone and
Medicine10,
(2012). Disponibleen:
.
91. Tokuyama, S.; Naka
ain Signaling
UnsaturatedFattyAci
92. Yeoh, N.; Burton, J. P.;Suppiah, P.;Reid, G.;Stebbings, S.The role of the microbiome in
rheumatic diseases. Curr Rheumatol Rep15, 314 (2013). Disponible en: http//dx.doi.org/
10.1007/s11926-‐012-‐0314-‐y.
93. Saag, K. G. Short-‐term and Long-‐term Safety of Glucocorticoids in Rheumatoid Arthritis.
BullNYUHospJtDis70(Suppl 1),S21-‐25(2012).
94. Cheng, O. T.; Souzdalnitski, D.;Vrooman, B.; Cheng, J. Evidencebasedknee injections for the
management of arthritis. PainMed June13, 740-‐753(2012).
95. Baggott, J. E.;Morgan, S. L. Methotrexate catabolism to 7-‐hydroxy methotrexate in
rheumatoid arthritis alters drug efficacy and retention and is reduced by folic acid
supplements. ArthritisRheum60, 2257-‐2261(2009).
96. O'Dell, J. R.; Mikuls, T. R.; Taylor, T. H.; Ahluwalia, V.; Brophy, M.; Warren, S. R.; et al.
Therapies for active rheumatoidarthritis aftermetotrexate failure. NEngl JMed369, 307-‐
318(2013).
97. Smolen, J. S.; Aletaha, D. Forget personalized medicine and focus on abating disease
activity. AnnRheumDis72, 3-‐6(2013).
98.
gic therapy for autoimmunediseases:
(2013).
Disponible
en:
99.
, A.; D’Amelio, R.; Signore, A. Biological
13).
100. Smolen, J. S.; Emery, P. I
(Suppl 1),
S2(2011). Disponibleen:
101. Al-‐Shakarchi, I.; Gullick
b for the
treatment of rheumatoid
, 653-‐666
(2013).
102. Smolen, J. S.; Schoels, M. M.; Nishimoto, N.; Breedveld, F.C.; Burmester, G.R.; Dougados, M.
et al. Consensus statement on blocking the effects of interleukin-‐6 and in particular by
thritis and other inflammatory
(2013).
Disponible en:
